FNCT Biotech
Seoul
About FNCT Biotech
FNCT Biotech develops antibody therapeutics for treating idiopathic pulmonary fibrosis (IPF). To create antibodies that target the underlying cause of IPF, the company's platform uses genetic engineering, providing patients with this medical need with a new treatment option.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2023)
- Website: fnctbiotech.com
- Phone: +82 02-2039-2601
Industries & Categories
Biopharma, Biotechnology, Health Care
Canonical: https://fsome.com/organization/fnct-biotech-19393 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.